Printer Friendly

GENSIA OBTAINS EXCLUSIVE EUROPEAN MARKETING RIGHTS TO INNOVATIVE CARDIOVASCULAR DRUG FROM OHMEDA

 SAN DIEGO, Oct. 6 /PRNewswire/ -- Gensia Inc. (NASDAQ: GNSA) announced today the signing of an exclusive distribution agreement with the Pharmaceutical Products Division of Ohmeda Inc. (formerly Anaquest) to distribute and market Brevibloc(R), an acute care cardiovascular drug, in Europe and certain other countries. Brevibloc is an ultra- short-acting intravenous beta-blocker indicated primarily for the treatment of perioperative tachycardia and hypertension with a secondary indication for the treatment of supraventricular tachycardia in emergency situations.
 Under the agreement, Gensia will make an initial payment to Ohmeda with two additional payments over the next two years in return for exclusive distribution and marketing rights in Europe. Gensia will also pay a royalty on sales to Ohmeda over a 10-year period. Ohmeda purchased Brevibloc from the developer and manufacturer, DuPont Merck, in 1992 and is currently marketing the drug in the United States and Canada. Brevibloc is also approved for marketing in 11 European countries with pricing applications pending in three additional European countries where the product has been approved. DuPont Merck has marketed and distributed Brevibloc in Europe for Ohmeda during a transition period and will continue to provide distribution and sales support for Gensia until the first quarter of 1994. Gensia plans to begin distributing the product through its own direct sales force in certain European countries in the first quarter of 1994. DuPont Merck will continue to manufacture the product for Gensia.
 "We are excited about the opportunity to market this innovative beta-blocker to cardiologists and anesthesiologists in Europe, which is the same target audience as for our lead cardiovascular products, Arasine(TM) and the GenESA(R) System. Brevibloc is currently approved for marketing in several key European countries which will allow us to develop the sales and marketing infrastructure necessary to effectively launch Arasine and the GenESA System, if approved by the European regulatory authorities," said David F. Hale, chairman, president and chief executive officer.
 "Brevibloc is particularly well suited for use during and immediately after surgery and in the CCU/ICU hospital settings. It has been widely accepted by physicians in the U.S., and with Ohmeda's marketing support, U.S. sales are expected to increase significantly from the original base of approximately $15 million. Although Brevibloc has received some marketing support in Europe, based on our marketing research and the fact that the product has not been launched in a number of European countries, we believe Brevibloc has not reached its full potential," added Hale.
 "We selected Gensia Inc. to be our European partner for Brevibloc because of the company's focus on cardiovascular and acute care hospital products. We are confident that Gensia will maximize the true potential of Brevibloc in Europe," said Paul Thomas, vice president of Marketing and Business Development of Ohmeda.
 Gensia Inc. is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases.
 -0- 10/6/93
 /CONTACT: Elizabeth A. Gard, Gensia, 619-622-3960/
 (GNSA)


CO: Gensia Inc.; Ohmeda Inc. ST: California IN: MTC SU: CON

MF-LS -- SD001 -- 9200 10/06/93 09:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 6, 1993
Words:515
Previous Article:UPDATED AND EXPANDED INDUSTRIAL LOCATOR DATABASE REALIZES 25 PERCENT GROWTH IN FIVE MONTHS
Next Article:HOUGHTEN PHARMACEUTICALS RAISES $6.6 MILLION FROM DOMAIN ASSOCIATES, OTHER EXISTING INVESTORS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters